Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets. The company was started in 1907 as the flagship company of the Alembic Group. In 2010, the company demerged its core pharmaceutical business (formulations) into a wholly-owned subsidiary, Alembic Pharma Ltd and after the demerger, APL became the flagship company of the Alembic Group.
The company lacks a durable competitive advantage as evidenced by its low average ROCE of 4.3% and high reliance on job-work in the API segment. While the real estate division benefits from a legacy land bank in Vadodara, this is a finite asset rather than a repeatable mechanism for excess returns.
Earnings are primarily deployed into real estate project development and maintaining a legacy API plant. While the company maintains a very low debt profile, the low ROCE suggests that reinvested capital is not generating high incremental returns for shareholders.
Five years out, the investment collapsed because the company remained a stagnant holding pen for legacy assets rather than a productive enterprise. The real estate division exhausted its prime Vadodara land bank, and without a repeatable acquisition strategy, development profits evaporated. Meanwhile, the API segment's reliance on low-margin job-work left it defenseless against rising input costs and global competition. The reported high net margins proved to be an accounting mirage, as the abysmal cash conversion ratio of 0.135 finally caught up with the income statement, revealing that earnings were never truly available to shareholders. Capital was further drained by opaque related-party dealings and high executive payouts, leaving the stock to trade at a permanent 'conglomerate discount' as the market realized no value would ever be unlocked.
RichFakir rates Alembic Ltd's business quality as mediocre — 46/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Alembic Ltd is trading about 29% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Alembic Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Alembic Ltd's fair value is about ₹123 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →